Wheeler Bio

Wheeler Bio is a private, US-based CDMO founded in 2018, focused on streamlining the early-stage development of biologics for biopharma companies. The company's innovative 'Modular CMC' service model and integrated Oklahoma City facilities aim to de-risk and accelerate the path from discovery to IND filing. With a recent oversubscribed Series A-1 financing and key leadership appointments, Wheeler is positioned for expansion as it capitalizes on industry trends toward outsourcing and supply chain security.

Modular CMC® - A novel service framework packaging custom drug development and CMC (Chemistry, Manufacturing, and Controls) services into defined modules to reduce risk, accelerate timelines, and provide cost predictability for biotech clients developing antibody-based therapeutics.

Competes with large, full-service CDMOs (e.g., Lonza, Catalent) and smaller, niche players focusing on early-stage development. Differentiation is based on the proprietary Modular CMC service model, integrated Oklahoma City facility for speed/security, and deep expertise in antibody-based modalities.